MAP2K1 and juvenile myelomonocytic leukemia: Given the involvement of the RAS/MAPK pathway in JMML, trametinib (a MEK1/2 inhibitor) has been investigated in the first clinical trial in the United States for pediatric patients with relapsed and refractory JMML [40] with preliminary data demonstrating four out of nine patients with clinical responses.